|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010802,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0205265,
umls-concept:C0205390,
umls-concept:C0439422,
umls-concept:C0439423,
umls-concept:C0522510,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C1521991,
umls-concept:C1552913,
umls-concept:C1555582,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2008-11-7
|
|
pubmed:abstractText |
We conducted a trial in 103 patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML) using imatinib 600 mg/day, with dose escalation to 800 mg/day for suboptimal response. The estimated cumulative incidences of complete cytogenetic response (CCR) by 12 and 24 months were 88% and 90%, and major molecular responses (MMRs) were 47% and 73%. In patients who maintained a daily average of 600 mg of imatinib for the first 6 months (n = 60), MMR rates by 12 and 24 months were 55% and 77% compared with 32% and 53% in patients averaging less than 600 mg (P = .037 and .016, respectively). Dose escalation was indicated for 17 patients before 12 months for failure to achieve, or maintain, major cytogenetic response at 6 months or CCR at 9 months but was only possible in 8 patients (47%). Dose escalation was indicated for 73 patients after 12 months because their BCR-ABL level remained more than 0.01% (international scale) and was possible in 45 of 73 (62%). Superior responses achieved in patients able to tolerate imatinib at 600 mg suggests that early dose intensity may be critical to optimize response in CP-CML. The trial was registered at www.ANZCTR.org.au as #ACTRN12607000614493.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:ArthurChrisC,
pubmed-author:Australasian Leukaemia and Lymphoma Group,
pubmed-author:BranfordSusanS,
pubmed-author:CatalanoJohnJ,
pubmed-author:CooneyJulianJ,
pubmed-author:DunkleyScottS,
pubmed-author:DurrantSimonS,
pubmed-author:FayKeithK,
pubmed-author:FilshieRobinR,
pubmed-author:GriggAndrewA,
pubmed-author:HertzbergMarkM,
pubmed-author:HughesTimothy PTP,
pubmed-author:JanuszewiczHenryH,
pubmed-author:JoskeDavidD,
pubmed-author:KoelmeyerRachelR,
pubmed-author:LeahyMichael FMF,
pubmed-author:LynchKevinK,
pubmed-author:MillsAnthony KAK,
pubmed-author:MortonJamesJ,
pubmed-author:ReynoldsJohnJ,
pubmed-author:RowlingsPhilipP,
pubmed-author:SchwarerAnthonyA,
pubmed-author:SeymourJohn FJF,
pubmed-author:TaylorKerryK,
pubmed-author:UnderhillCraigC,
pubmed-author:WhiteDeborah LDL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3965-73
|
|
pubmed:meshHeading |
pubmed-meshheading:18768781-Adolescent,
pubmed-meshheading:18768781-Adult,
pubmed-meshheading:18768781-Aged,
pubmed-meshheading:18768781-Antineoplastic Agents,
pubmed-meshheading:18768781-Dose-Response Relationship, Drug,
pubmed-meshheading:18768781-Female,
pubmed-meshheading:18768781-Fusion Proteins, bcr-abl,
pubmed-meshheading:18768781-Humans,
pubmed-meshheading:18768781-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18768781-Male,
pubmed-meshheading:18768781-Middle Aged,
pubmed-meshheading:18768781-Piperazines,
pubmed-meshheading:18768781-Pyrimidines,
pubmed-meshheading:18768781-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
|
|
pubmed:affiliation |
Institute of Medical and Veterinary Science, Adelaide, Australia. timothy.hughes@imvs.sa.gov.au
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
